Thiry Justine, Broze Guy, Pestieau Aude, Tatton Andrew S, Baumans France, Damblon Christian, Krier Fabrice, Evrard Brigitte
Laboratory of Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000, Liege, Belgium.
Center for Education and Research on Macromolecules, University of Liege, Chemistry Department, B6a, Sart-Tilman, Liege, Belgium.
Eur J Pharm Sci. 2016 Mar 31;85:94-105. doi: 10.1016/j.ejps.2016.02.002. Epub 2016 Feb 2.
The difficulty to find a relevant in vitro dissolution test to evaluate poorly soluble drugs is a well-known issue. One way to enhance their aqueous solubility is to formulate them as amorphous solid dispersions. In this study, three formulations containing itraconazole (ITZ), a model drug, were tested in seven different conditions (different USP apparatuses and different media). Two of the formulations were amorphous solid dispersions namely Sporanox®, the marketed product, and extrudates composed of Soluplus® and ITZ produced by hot melt extrusion; and the last one was pure crystalline ITZ capsules. After each test, a ranking of the formulations was established. Surprisingly, the two amorphous solid dispersions exhibited very different behavior depending primarily on the dissolution media. Indeed, the extrudates showed a better release profile than Sporanox® in non-sink and in biphasic conditions, whilst Sporanox® showed a higher release profile than the extrudates in sink and fasted simulated gastric conditions. The disintegration, dynamic light scattering and nuclear magnetic resonance results highlighted the presence of interaction between the surfactants and Soluplus®, which slowed down the erosion of the polymer matrix. Indeed, the negative charge of sodium dodecyl sulfate (SDS) and bile salts interacted with the surface of the extrudates that formed a barrier through which the water hardly diffused. Moreover, Soluplus® and SDS formed mixed micelles in solution in which ITZ interacts with SDS, but no longer with Soluplus®. Regarding the biphasic dissolution test, the interactions between the octanol dissolved in the aqueous media disrupted the polymer--ITZ system leading to a reduced release of ITZ from Sporanox®, whilst it had no influence on the extrudates. All together these results pointed out the difficulty of finding a suitable in vitro dissolution test due to interactions between the excipients that complicates the prediction of the behavior of these solid dispersions in vivo.
寻找相关的体外溶出试验来评估难溶性药物一直是个众所周知的难题。提高其水溶性的一种方法是将它们制成无定形固体分散体。在本研究中,对含有模型药物伊曲康唑(ITZ)的三种制剂在七种不同条件(不同的美国药典装置和不同的介质)下进行了测试。其中两种制剂是无定形固体分散体,即市售产品斯皮仁诺®,以及通过热熔挤出法制备的由固体分散体辅料和伊曲康唑组成的挤出物;最后一种是纯结晶伊曲康唑胶囊。每次测试后,对这些制剂进行了排名。令人惊讶的是,这两种无定形固体分散体表现出非常不同的行为,主要取决于溶出介质。实际上,在非漏槽和双相条件下,挤出物显示出比斯皮仁诺®更好的释放曲线,而在漏槽和禁食模拟胃条件下,斯皮仁诺®显示出比挤出物更高的释放曲线。崩解、动态光散射和核磁共振结果突出了表面活性剂与固体分散体辅料之间存在相互作用,这减缓了聚合物基质的侵蚀。实际上,十二烷基硫酸钠(SDS)和胆盐的负电荷与挤出物表面相互作用,形成了一层水几乎难以扩散通过的屏障。此外,固体分散体辅料和SDS在溶液中形成混合胶束,其中伊曲康唑与SDS相互作用,但不再与固体分散体辅料相互作用。关于双相溶出试验,溶解在水性介质中的辛醇之间的相互作用破坏了聚合物 - 伊曲康唑体系,导致伊曲康唑从斯皮仁诺®中的释放减少,而对挤出物没有影响。所有这些结果都指出,由于辅料之间的相互作用使得预测这些固体分散体在体内的行为变得复杂,因此难以找到合适的体外溶出试验。